About
Light roast coffee is produced by roasting green Coffea arabica or Coffea canephora beans at lower temperatures (approximately 175–205°C), yielding a lighter brown color, higher acidity, and greater retention of chlorogenic acids and antioxidants than darker roasts. It is consumed as a brewed beverage and used as a flavoring ingredient in a wide variety of food products including ice cream, confectionery, and baked goods.
Safety summary
Light roast coffee contains relatively higher acrylamide levels than darker roasts due to the inverse relationship between roasting degree and acrylamide concentration, though levels in very light to medium roasts typically remain below the EU benchmark of 400 µg/kg; acrylamide is classified by IARC as a probable human carcinogen (Group 2A) but has not been conclusively shown to cause cancer in humans at typical dietary exposures. IARC re-evaluated drinking coffee in 2016 (Monographs Vol. 116) and reclassified it to Group 3 (not classifiable as to carcinogenicity to humans), noting probable protective effects against liver and uterine endometrial cancers. Caffeine content in light roast coffee warrants restriction in pregnant women, infants, children, and individuals with cardiovascular or anxiety-related conditions.
Regulatory landscape
| Jurisdiction | Status | Note |
|---|---|---|
| EFSA (European Food Safety Authority) (European Union) | Restricted | Coffee itself is permitted as a food. Commission Regulation (EU) 2017/2158 sets acrylamide benchmark (mitigation) levels: 400 µg/kg for roasted coffee and 850 µg/kg for instant (soluble) coffee. Light roasts typically fall at or below the 400 µg/kg benchmark, while medium-dark to dark roasts may exceed it. Operators are required to implement mitigation measures and monitor acrylamide levels.source |
| FDA (Food and Drug Administration) (United States) | Approved | California Proposition 65 (state-level): OEHHA issued a regulation in October 2019 exempting coffee from Prop 65 cancer warning label requirements for acrylamide, concluding that coffee consumption does not pose a significant cancer risk at typical intake levels.source |
Who should approach with care
Research citations
- 1PubMed. Dietary acrylamide and human cancer; even after 20 years of research an open question, 2022. pmc.ncbi.nlm.nih.gov
- 2PubMed. Safest Roasting Times of Coffee To Reduce Carcinogenicity, 2022. pubmed.ncbi.nlm.nih.gov
- 3PubMed. Acrylamide formation and antioxidant activity in coffee during roasting — A systematic study, 2020. pubmed.ncbi.nlm.nih.gov
- 4PubMed. Optimization of the roasting conditions to lower acrylamide content and improve the nutrient composition and antioxidant properties of Coffea arabica, 2020. pmc.ncbi.nlm.nih.gov
- 5IARC. Drinking Coffee, Mate, and Very Hot Beverages — IARC Monographs Volume 116, 2016. iarc.who.int
